Skip to main content
Premium Trial:

Request an Annual Quote

DNAStar Taps Infogen for European Sales

NEW YORK (GenomeWeb News) — DNAStar has signed up Infogen to distribute its gene expression software in several European nations, the company said today.

Under the agreement, Infogen has gained the rights to sell the ArrayStar software, which is used to visualize and analyze gene expression data, in the UK, Ireland, Italy, Spain, and Greece.

The ArrayStar line was launched in 2007, and it has been expanded to handle applications from data generated by next-generation sequencing platforms, DNAStar said.

“We have seen continuing demand for ArrayStar and felt that our best way to capture this business was by adding to our distribution organization,” Bob Steinhauser, DNAStar’s director of marketing, said in a statement.

Steinhauser said Infogen possesses the “technical expertise required to properly sell and support” the ArrayStar software. He added that the company, which has bases in the UK and in Italy, has important knowledge of local markets

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.